The global metabolomics market is highly competitive and fragmented in nature. Prominent players in the global metabolomics market are Thermo Fisher Scientific (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Waters Corporation (U.S.), and Shimadzu Corporation (Japan). Other leading players in this market include Bio-Rad Laboratories (U.S.), Bruker Corporation (U.S.), Biocrates Life Sciences AG (Austria), Human Metabolome Technologies Inc. (Japan), LECO Corporation (U.S.), and Metabolon Inc. (U.S.). A majority of the leading players in this market are based in developed countries across North America and Europe.
Thermo Fisher Scientific, Inc. (U.S.) held the leading position in the global metabolomics market in 2015. Its prominence in this market can be attributed to its diversified product portfolio that includes a wide range of products for metabolomics instrumentation tools and services. The company strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for the growing metabolomics market. Moreover, the company has a wide geographic presence across North America, Europe, the Middle East & Africa, and Asia. The company has also focused on a variety of strategies, such as agreements, product launches, and expansions, to increase its share in the metabolomics market. For instance, in September 2016, Thermo Fisher Scientific, Inc. (U.S.) launched the Thermo Scientific Exactive GC Orbitrap GC-MS system designed to enable powerful qualitative and quantitative analysis for GC-MS applications. This helped the company to better serve researchers in the fields of food safety, environmental, industrial, forensics, and anti-doping.
Agilent Technologies (U.S.) is another leading company in the global metabolomics market. The company has maintained its leadership position through its strong presence across the globe, covering major markets such as North America, Europe, and Asia-Pacific. The company has a strong product portfolio and its FDA and CE Mark-approved products have helped it to further enhance its presence in the metabolomics market. The company has adopted new product launches as its key strategy, followed by agreements and collaborations, to maintain its leading position and increase its market share. For instance, in December 2016, Agilent Technologies, Inc. (U.S.) collaborated with Transcriptic Inc. (U.S.), a robotic cloud-based biotechnology laboratory, to develop and provide rapid and efficient technologies for broad scale synthetic and discovery. This collaboration helped Agilent enhance its market position by serving a global customer base with automated and robotics workflows for bioreagent optimization.
In the past three years, a majority of the top players have adopted product launches; acquisitions, agreements, collaborations, and partnerships; and geographic expansions as their key growth strategies. Product launches was the most preferred strategy adopted by key players in the global metabolomics market.
Metabolomics Market by Product (GC, HPLC, UPLC, NMR, Mass Spectrometry, Surface based mass analysis, Bioinformatics), Application (Biomarker & Drug Discovery, Nutrigenomics, Toxicology), Indication (Oncology, Cardiology, Inborn Errors) - Forecast to 2021
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE